Market cap
$122 Mln
Revenue (TTM)
$243 Mln
P/E Ratio
2.9
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.4
-
Debt to Equity
0
-
Book Value
$0.4
-
EPS
$0.2
-
Face value
--
-
Shares outstanding
243,186,939
10 Years Aggregate
CFO
$-333.45 Mln
EBITDA
$-354.93 Mln
Net Profit
$-414.47 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vaxart (VXRT)
| 45.3 | 11.1 | -21.3 | 34.5 | -14.0 | -44.0 | -28.8 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Vaxart (VXRT)
| -48.0 | 15.5 | -40.4 | -84.7 | 9.8 | 1,529.1 | -81.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vaxart (VXRT)
|
0.5 | 121.6 | 243.1 | 38.6 | 17.0 | 45.4 | 2.9 | 1.5 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Vaxart (VXRT)
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes... norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Read more
-
Senior VP & Chief Scientific Officer
Dr. Sean N. Tucker Ph.D.
-
Senior VP & Chief Scientific Officer
Dr. Sean N. Tucker Ph.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vaxart (VXRT)
What is the current share price of Vaxart Inc (VXRT) Today?
The share price of Vaxart Inc (VXRT) is $0.50 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Vaxart Inc (VXRT) has given a return of -14.04% in the last 3 years.
What is the current PB & PE ratio of Vaxart Inc (VXRT)?
The P/E ratio of Vaxart Inc (VXRT) is 2.94 times as on 28-Aug-2026.
The P/B ratio of Vaxart Inc (VXRT) is 1.49 times as on 28-Aug-2026, a 71 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
4.85 |
0.90 |
2024 |
-2.25 |
2.56 |
2023 |
-1.23 |
1.76 |
2022 |
-1.58 |
1.54 |
2021 |
-15.22 |
5.72 |
What is the 52 Week High and Low of Vaxart Inc (VXRT)?
The 52-week high and low of Vaxart Inc (VXRT) are Rs 0.84 and Rs 0.31 as of 31-Aug-2026.
What is the market cap of Vaxart Inc (VXRT)?
Vaxart Inc (VXRT) has a market capitalisation of $ 122 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Vaxart Inc (VXRT)?
Before investing in Vaxart Inc (VXRT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.